Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis

Company Overview

Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs. Preclinical and early clinical studies are aimed at demonstrating safety, tolerability and proof of concept in patient populations with high unmet medical need. The company leverages strategic collaborations and research partnerships to accelerate development and expand its scientific expertise.

Founded in the United States and headquartered in San Diego, California, Milestone Pharmaceuticals operates with a management team experienced in respiratory drug development. The company continues to pursue regulatory pathways for its lead programs and is preparing for later-stage clinical trials. Through a combination of internal innovation and external partnerships, Milestone seeks to bring new treatment options to patients suffering from debilitating respiratory disorders.

Key Stats

• Today's Range: $1.93 to $2.05
• 50-Day Range: $1.64 to $2.18
• 52-Week Range: $0.63 to $2.75
• Volume: 1.85 million shs
• Average Volume: 1.63 million shs
• Market Capitalization: $172.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Hold

Milestone Pharmaceuticals Stock Analysis - MarketRank™

Milestone Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 631st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Milestone Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Milestone Pharmaceuticals has a consensus price target of $4.50, representing about 123.3% upside from its current price of $2.02.

Amount of Analyst Coverage

Milestone Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($0.62) to ($1.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Milestone Pharmaceuticals is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Milestone Pharmaceuticals is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Milestone Pharmaceuticals has a P/B Ratio of 8.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.92% of the outstanding shares of Milestone Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Milestone Pharmaceuticals has recently decreased by 14.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Milestone Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Milestone Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.92% of the outstanding shares of Milestone Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Milestone Pharmaceuticals has recently decreased by 14.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

34 people have searched for MIST on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.50% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MIST Stock Analysis - Frequently Asked Questions

How have MIST shares performed this year?

Milestone Pharmaceuticals' stock was trading at $2.36 on January 1st, 2025. Since then, MIST shares have decreased by 14.6% and is now trading at $2.0150.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.02.

When did Milestone Pharmaceuticals IPO?

Milestone Pharmaceuticals (MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Who are Milestone Pharmaceuticals' major shareholders?

Top institutional investors of Milestone Pharmaceuticals include Simplify Asset Management Inc. (3.33%), Stephenson & Company Inc. (0.02%) and Sapient Capital LLC (0.01%). Insiders that own company stock include David Bharucha and Debra K Liebert.
View institutional ownership trends.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray Brands (TLRY), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), Vaxart (VXRT) and Aquestive Therapeutics (AQST).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MIST
• CIK: 1408443
• Web: www.milestonepharma.com
• Phone: (514) 336-0444
• Fax: N/A
• Employees: 30
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Milestone Pharmaceuticals: $4.50
• High Price Target: $5.00
• Low Price Target: $4.00
• Potential Upside/Downside: +126.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,672.29%
• Return on Assets: -83.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.97
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 169.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 7.96

Miscellaneous

• Outstanding Shares: 84,990,000
• Free Float: 68,420,000
• Market Cap: $169.13 million
• Optionable: Optionable
• Beta: 0.61